Enter inventor name

Francoise Bono

USPTO Granted Patents = 15 (Patent Applications = 1)

CIPO Patents = 7 (Patent Applications = 4)

Average Co-Inventor Count = 4.2

ph-index = 2

Forward Citations = 20(Granted Patents)

Location History:

Toulouse, FR (2008 - 2015)
Paris, FR (2012 - 2015)

Company Filing History:

Years Active: 2008-2015

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9120819 - FGF-receptor agonist dimeric compounds (2015-09-01),

2. 8957211 - (Heterocycle/condensed piperidine)-(piperazinyl)-1-alkanone or (heterocycle/condensed pyrrolidine)-(piperazinyl)-1-alkanone derivatives and use thereof as p75 inhibitors (2015-02-17),

3. 8906924 - (heterocycle/tetrahydropyridine)-(piperazinyl)-1-alcanone and (heterocycle/dihydropyrrolidine)-(piperazinyl)-1-alcanone derivatives, and use thereof as p75 inhibitors (2014-12-09),

4. 8633216 - Imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same (2014-01-21),

5. 8586602 - Derivatives of 7 alkynyl-1,8 naphthyridones, preparation method thereof and use of same in therapeutics (2013-11-19),

6. 8580790 - (Heterocycle/condensed piperidine)-(piperazinyl)-1-alkanone or (heterocycle/condensed pyrrolidine)-(piperazinyl)-1-alkanone derivatives and use thereof as p75 inhibitors (2013-11-12),

7. 8519143 - Derivatives of (bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors (2013-08-27),

8. 8518947 - (Heterocycle/tetrahydropyridine)-(piperazinyl)-1-alcanone and (heterocycle/dihydropyrrolidine)-(piperazinyl)-1-alcanone derivatives, and use thereof as p75 inhibitors (2013-08-27),

9. 8263614 - Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics (2012-09-11),

10. 8247404 - Derivatives of 2-oxoalkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same (2012-08-21),

11. 8034828 - Use of FGF inhibiting substituted 1,2,3 indolizine derivatives in the preparation of medicaments which can be used to treat diseases linked to pathological choroidal angiogenesis (2011-10-11),

12. 8008321 - Imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same (2011-08-30),

13. 7803811 - 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, method for preparing them and pharmaceutical compositions containing them (2010-09-28),

14. 7553845 - Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives (2009-06-30),

15. 7442708 - 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same (2008-10-28),

Title: Innovations by Francoise Bono in the Field of Pharmaceuticals

Introduction

Francoise Bono is a notable inventor hailing from Toulouse, France. With an impressive portfolio of 15 patents, he has significantly contributed to the field of pharmaceuticals, particularly in the development of FGF-receptor agonist compounds and their therapeutic applications.

Latest Patents

Bono's latest patents include groundbreaking work on FGF-receptor agonist dimeric compounds. These compounds are represented by the general formula M1-L-M2, where M1 and M2 signify monomer units and L serves as a linker group. Additionally, he has focused on derivatives such as (heterocycle/condensed piperidine)-(piperazinyl)-1-alkanone and (heterocycle/condensed pyrrolidine)-(piperazinyl)-1-alkanone, which function as p75 inhibitors. This innovative research is vital for therapeutic advancements in various medical areas.

Career Highlights

Throughout his career, Francoise Bono has made significant strides in his field while working with prominent companies such as Sanofi and Sanofi-Aventis. His work within these organizations has led to meaningful developments in pharmaceutical research and innovation.

Collaborations

Bono has collaborated with several notable colleagues, including Marco Baroni and Sandrine Delbary-Gossart. These partnerships have undoubtedly enriched the quality and scope of his research efforts, contributing to the successful outcomes of his inventions.

Conclusion

Francoise Bono stands out as a leading inventor in the pharmaceutical industry, recognized for his 15 patents and ongoing contributions to scientific advancements. His innovations, particularly concerning FGF-receptor agonist compounds, highlight his commitment to enhancing therapeutic options and improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com